AcquisitionOther
Epizyme, Inc. acquired Epizyme, expanding
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Epizyme, Inc. -> Epizyme, expanding · $1.45
As part of the transaction, Ipsen will also acquire Epizymes first-in-class, oral SETD2 inhibitor development candidate, EZM0414, which was granted FDA Fast Track status and is currently under evaluation in a recently initiated Phase I/Ib trial in adult patie
Open source record (SEC) ↗